Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Transmembrane Transporters >  Sodium Channel Inhibitor >  Ibutilide fumarate

Ibutilide fumarate

Basic information Safety Related Supplier
Ibutilide fumarate Basic information
Ibutilide fumarate Chemical Properties
  • Melting point:112-117?C
  • RTECS PB0475700
  • storage temp. Refrigerator
  • solubility H2O: >20mg/mL
  • form solid
  • color off-white to tan
  • λmax267nm(EtOH)(lit.)
  • Merck 14,4883
  • CAS DataBase Reference122647-32-9(CAS DataBase Reference)
Safety Information
  • Hazard Codes Xn
  • Risk Statements 22
  • WGK Germany 1
  • HS Code 2935904000
Ibutilide fumarate Usage And Synthesis
  • DescriptionCovert was launched in the US and UK for treatment of atrial fibrillation and flutter and can be synthesized in three steps from N-phenyl rnethanesulfonamide. While ibutilide has an asymmetric center, it has been determined that the racemate is equipotent with either enantiomer. The antiarrhythmic action is derived from the compounds ability to prolong the action potential duration and lengthen the refractory period of myocardial tissue. Class Ⅲ antiarrhythrnic agents accomplish this by blocking outward potassium channels, however, ibutilide elicits the same effect by activation of slow inward sodium channels. Recent evidence indicates that it also is a potent blocker of the rapidly acting delayed rectifier potassium current (lkr)and may block the ATP-inhibited potassium channel.
  • Chemical PropertiesWhite to Off-White Solid
  • OriginatorPharmacia & Upjohn (UK)
  • UsesA methanesulfonanilide antiarrhythmic agent; prologns myocardial action potential duration, predominantly by activation of slow inward sodium current. Antiarrhythmic (class III).
  • brand nameInocor (Sterling Winthrop);Corvert.
  • Clinical UseIbutilide (Corvert) is a structural analog of sotalol and produces cardiac electrophysiological effects similar to those of the antiarrhythmic agents in class III.
    Ibutilide is approved for the chemical cardioversion of recent-onset atrial fibrillation and atrial flutter. Ibutilide appears to be more effective in terminating atrial flutter than atrial fibrillation. It can also lower the defibrillation threshold for atrial fibrillation resistant to chemical cardioversion.
  • Side effectsThe major adverse effect associated with the use of ibutilide is the risk of torsades de pointes due to QT prolongation. Other reported adverse cardiovascular events (all 2%) include hypotension and hypertension, bradycardia and tachycardia, and varying degrees of A-V block. The incidence of noncardiac adverse events with the exception of nausea does not differ from that of placebo.
  • Drug interactionsIbutilide has significant drug interactions.
  • PrecautionsContraindications to the use of ibutilide include baseline prolongation of the QT interval, use of other QTprolonging drugs, history of torsades de pointes, hypersensitivity to ibutilide, uncorrected hypokalemia or hypomagnesemia, and pregnancy or breast-feeding.
Ibutilide fumarate(122647-32-9)Related Product Information
Ibutilide fumarateSupplierMore
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-
  • Company Name:Alfa Aesar
  • Tel:400-610-6006
  • Company Name:TCI (Shanghai) Development Co., Ltd.
  • Tel:021-67121386 / 800-988-0390
  • Company Name:Pure Chemistry Scientific Inc.
  • Tel:001-857-928-2050 or 1-888-588-9418